Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597493 · ClinicalTrials.gov registry record · Phase 2
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
A Phase 2 study of Recurrent Glioblastoma Multiforme, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00597493: Completed Phase 2 study of Recurrent Glioblastoma Multiforme, sponsored by Duke University.
NCT00597493 is a Phase 2 study of Recurrent Glioblastoma Multiforme that has completed, run by Duke University. The registered enrollment target is 32 participants, below the 98-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00597493, a Phase 2 study of Recurrent Glioblastoma Multiforme, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
PURPOSE AND OBJECTIVES: Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS. Secondary Objectives To evaluate the safety and toxicity of combination therapy using Sorafenib plus temozolomide; To determine the pharmacokinetics of Sorafenib when combined with temozolomide in patients on and not on concurrent EIAC medications.
Primary Outcome
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause.
Conditions Studied
Interventions
- DRUG Sorafenib and Temozolomide
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00597493 record still lists
NCT00597493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 98-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Sorafenib and Temozolomide is the first listed.
NCT00597493 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00597493 about?
NCT00597493 is a clinical study titled "Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM". PURPOSE AND OBJECTIVES: Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS. Secondary Objectives To evaluate the safety and toxicity of combination therapy using Sorafenib p...
What is the current status of trial NCT00597493?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-09. Estimated completion is 2010-12.
What conditions does trial NCT00597493 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme.
What interventions are being tested in trial NCT00597493?
The interventions under investigation include: Sorafenib and Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00597493?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00597493 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 2
-
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
RECRUITING · Phase 1
-
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
COMPLETED · Phase 1
-
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 3
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia